Apalutamide

證據等級: L5

預測適應症: 0 個

Apalutamide: Androgen Receptor Inhibitor — Insufficient Data for Repurposing Evaluation

One-Sentence Summary

Apalutamide (Erleada®) is a non-steroidal androgen receptor (AR) signaling inhibitor approved for prostate cancer treatment, currently marketed in Malaysia under one registered licence. However, the current Evidence Pack contains no TxGNN-predicted new indications, and critical data fields — including approved indication text, mechanism of action details, and safety warnings — are absent or incomplete. As a result, a full repurposing evaluation cannot be completed at this stage; the recommended decision is Hold pending data remediation.

Quick Overview

Item	Content
Original Indication	Prostate cancer (based on known pharmacological class; approved indication text not retrieved from this Evidence Pack)
Predicted New Indication	— No TxGNN prediction available
TxGNN Prediction Score	— Not applicable
Evidence Level	L5 (model prediction not available; no supporting studies retrievable from this pack)
Malaysia Market Status	✓ Marketed
Number of Registrations	1
Recommended Decision	Hold

Why is This Prediction Reasonable?

No TxGNN-predicted new indication is present in the Evidence Pack (predicted_indications: []). Therefore, a mechanistic repurposing hypothesis cannot be formally evaluated at this time.

For background context: Apalutamide is a small-molecule androgen receptor inhibitor that binds directly to the ligand-binding domain of AR, blocking nuclear translocation, DNA binding, and transcriptional activation of androgen-responsive genes. It belongs to the same pharmacological class as enzalutamide and darolutamide. Its established efficacy in hormone-sensitive and castration-resistant prostate cancer is well documented in the SPARTAN and TITAN Phase 3 trials.

Currently, detailed mechanism of action data is not available in the Evidence Pack. Pending completion of DrugBank MOA data retrieval (Data Gap DG002) and TxGNN scoring, a formal mechanistic bridge to any candidate new indication cannot be constructed.

Clinical Trial Evidence

No TxGNN-predicted indication is available; therefore, targeted clinical trial evidence cannot be retrieved from the Evidence Pack.

Currently no related clinical trials are linked to a repurposing prediction for this candidate.

Literature Evidence

Currently no related literature is available for a repurposing prediction in this Evidence Pack.

Malaysia Market Information

The Evidence Pack confirms 1 registered licence in Malaysia; however, all licence detail fields (licence number, product name, dosage form, manufacturer, approved indication text) were returned as empty strings and could not be populated.

Authorization Number	Product Name	Dosage Form	Approved Indication
— (not retrieved)	— (not retrieved)	— (not retrieved)	— (not retrieved)

Action required: Download the NPRA product registration record to populate all licence fields.

Cytotoxicity

Apalutamide is an antiandrogen / androgen receptor signaling inhibitor — it is classified as a targeted antineoplastic agent, not a conventional cytotoxic.

Item	Content
Cytotoxicity Classification	Targeted therapy — non-steroidal androgen receptor inhibitor (not a conventional cytotoxic/DNA-damaging agent)
Myelosuppression Risk	Low (AR inhibitors do not typically cause significant myelosuppression; haematological monitoring still recommended)
Emetogenicity Classification	Minimal to low
Monitoring Items	CBC, liver function tests (LFTs), thyroid function (hypothyroidism reported), falls/fracture risk assessment, seizure history
Handling Protection	Follows standard oral antineoplastic handling precautions; avoid crushing tablets; use gloves when handling

Safety Considerations

Key warnings and contraindications were not retrievable from the current Evidence Pack (Data Gap DG001 — TFDA package insert not parsed). No drug–drug interaction data was found in the DDI query.

Please refer to the approved Malaysian package insert and the Erleada® prescribing information for complete safety information, including:

Seizure risk (particularly in patients with predisposing factors)
Falls and fractures
Cardiovascular events
Hypothyroidism
Embryo-foetal toxicity (contraindicated in females of reproductive potential)
Strong CYP3A4 and CYP2C19 induction (clinically significant DDI potential, despite not_found status in automated DDI query — manual review is essential)

Conclusion and Next Steps

Decision: Hold

Rationale: The Evidence Pack for Apalutamide (DB11901) is currently insufficient to support a repurposing evaluation: the predicted_indications array is empty, approved indication text was not retrieved, mechanism of action data is absent, and safety warnings/contraindications have not been parsed. No recommendation can be made without at minimum a TxGNN prediction score and a candidate new indication.

To proceed, the following is needed:

DG001 (Blocking) — Download and parse the TFDA/NPRA package insert PDF to extract approved indication text, key warnings, and contraindications
DG002 (High) — Query DrugBank API to retrieve mechanism of action (MOA) for DB11901
Re-run TxGNN prediction pipeline — Confirm that Apalutamide (DB11901) is included in the KG prediction run and that repurposing_candidates.csv contains scored disease candidates
Populate licence details — Retrieve full NPRA registration record (licence number, product name, dosage form, manufacturer)
Manual DDI review — Despite the automated not_found result, Apalutamide is a potent CYP3A4/2C19/P-gp inducer; a manual DDI review against common co-medications is required before any repurposing protocol is initiated
Re-generate Evidence Pack — Once DG001 and DG002 are resolved and TxGNN predictions are available, reissue Evidence Pack v5 for full evaluation
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.